 |
|
Continuous vs Episodic Prophylactic Treatment With Amiodarone for the Prevention of Atrial FibrillationA Randomized Trial
Sheba Ahmed, MD;
Michiel Rienstra, MD, PhD;
Harry J. G. M. Crijns, MD, PhD;
Thera P. Links, MD, PhD;
Ans C. P. Wiesfeld, MD, PhD;
Hans L. Hillege, MD, PhD;
Hans A. Bosker, MD, PhD;
Dirk J. A. Lok, MD;
Dirk J. Van Veldhuisen, MD, PhD;
Isabelle C. Van Gelder, MD, PhD; for the CONVERT Investigators
JAMA. 2008;300(15):1784-1792.
Context Amiodarone effectively suppresses atrial fibrillation but causes many adverse events.
Objective To compare major events in patients randomized to receive episodic amiodarone treatment with those who received continuous amiodarone treatment while still aiming to prevent atrial fibrillation.
Design, Setting, and Participants A randomized trial of 209 ambulatory patients with recurrent symptomatic persistent atrial fibrillation, conducted from December 2002 through March 2007 at 7 Dutch medical centers.
Intervention Patients were randomly assigned to receive either episodic or continuous amiodarone treatment after electrical cardioversion following amiodarone loading. Episodic amiodarone treatment was discontinued after a month of sinus rhythm and reinitiated if atrial fibrillation relapsed (1 month peri–electrical cardioversion). In the continuous treatment group amiodarone was maintained throughout.
Main Outcome Measures The primary end point was a composite of amiodarone and underlying heart disease–related major events. The secondary end points were all-cause mortality and cardiovascular hospitalizations.
Results After a median follow-up of 2.1 years (range, 0.4-2.5 years), 51 (48%) of those receiving episodic treatment vs 64 (62%) receiving continuous treatment had sinus rhythm (P = .05). There were 85 atrial fibrillation recurrences (80%) among the episodic treatment group vs 56 (54%) in the continuous treatment group (P < .001). No significant difference existed in the incidence of the primary composite end point between each group (37 [35%] episodic vs 34 [33%] continuous; incidence rate difference, 0.2; 95% confidence interval [CI], –10.2 to 10.6). However, there were nonstatistically significant differences in the incidence of amiodarone-related major events (20 [19%] episodic vs 25 [24%] continuous; incidence rate difference, –2.0; 95% CI, –8.7 to 4.6) and underlying heart disease–related major events (17 [16%] episodic vs 9 [9%] continuous; incidence rate difference, 3.6; 95% CI, –1.6 to 8.7). All-cause mortality and cardiovascular hospitalizations were higher among those receiving episodic treatment (56 [53%] vs 35 [34%], P = .02).
Conclusions In this study population, there was no difference in the composite of amiodarone and cardiac major adverse events between groups. However, patients receiving episodic treatment had a significantly increased rate of atrial fibrillation recurrence and a significantly higher rate of all-cause mortality and cardiovascular hospitalizations.
Trial Registration clinicaltrials.gov Identifier: NCT00392431
Author Affiliations: Departments of Cardiology (Drs Ahmed, Rienstra, Wiesfeld, Van Veldhuisen, and Van Gelder), Internal Medicine (Dr Links), and Trial Coordination Center (Dr Hillege), University Medical Center Groningen, University of Groningen, Groningen; Interuniversity Cardiology Institute Netherlands, Utrecht (Dr Van Gelder); Department of Cardiology, Maastricht University Medical Center, Maastricht (Dr Crijns); Department of Cardiology, Rijnstate Hospital, Arnhem (Dr Bosker), Department of Cardiology, Deventer Hospital, Deventer (Dr Lok), the Netherlands.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Treatment With Amiodarone to Prevent Atrial Fibrillation
Pasquale Santangeli, Antonio Dello Russo, and Fulvio Bellocci
JAMA. 2009;301(10):1019.
EXTRACT
| FULL TEXT
Treatment With Amiodarone to Prevent Atrial Fibrillation
Madhavi Bollu, Ravi K. Bobba, and Edward L. Arsura
JAMA. 2009;301(10):1019-1020.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Orr and Ahlskog
Arch Neurol 2009;66:865-869.
ABSTRACT
| FULL TEXT
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Kirchhof et al.
Europace 2009;11:860-885.
FULL TEXT
Will we be able to predict in which atrial fibrillation patients a rhythm control strategy will be successful?
Smit and Van Gelder
Europace 2009;11:846-847.
FULL TEXT
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'
Kirchhof et al.
Eur Heart J 2009;0:ehp235v1-ehp235.
ABSTRACT
| FULL TEXT
Treatment With Amiodarone to Prevent Atrial Fibrillation
Santangeli et al.
JAMA 2009;301:1019-1019.
FULL TEXT
Treatment With Amiodarone to Prevent Atrial Fibrillation
Bollu et al.
JAMA 2009;301:1019-1020.
FULL TEXT
Is inflammation a risk factor for recurrent atrial fibrillation?
Smit and Van Gelder
Europace 2009;11:138-139.
FULL TEXT
CHAPTER 11 Clinical Pharmacology of Cardiovascular Drugs
Zannad et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT
| FULL TEXT
CHAPTER 29 Atrial Fibrillation
Camm et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT
| FULL TEXT
Amiodarone for Sinus Rhythm Maintenance: Continuous Dosing Is Best
Journal Watch Cardiology 2008;2008:1-1.
FULL TEXT
|
